Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-08

Clinical Trial Update: A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of Iclepertin in schizophrenia participants has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Iclepertin

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2026-04-08